The infrastructure investments in artificial intelligence (AI) by major U.S. tech companies are putting pressure on the corporate bond market. Corporate bond issuance in the U.S. is expected to reach $200 billion in September, which could serve as a litmus test for the bond market. As the demand for funding for AI infrastructure investments rises, corporate debt financing is increasing. The issuance of U.S. investment-grade corporate bonds is projected to rise by 38% year-on-year by 2026, with an annual issuance volume expected to reach $2.1 trillion. Major tech companies such as Microsoft, Alphabet, Amazon, Meta, and Oracle are ramping up investments in data centers, power, and computing equipment to compete in the AI services market. In the past, AI investments were covered by internal cash flows, but as competition intensifies, the reliance on bond market financing is growing. The supply of AI-related bonds is nearing a limit that could disrupt the market, and if AI revenue growth cannot support large-scale investments, some capital expenditures may face the risk of insufficient returns. Currently, market attention is shifting from whether AI can generate profits to whether large-scale infrastructure investments can lead to sufficient cash flow. If corporate bond issuance reaches $200 billion in September, AI investments are likely to influence capital allocation in the bond market as well.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.
